| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Bendazol targets nitric oxide synthase (NOS) as an activator. It enhances NOS activity in renal glomeruli and collecting tubules. The compound also acts as a vasodilator, dilating blood vessels and reducing peripheral resistance. It inhibits aminopyrine N-demethylase activity in hepatic microsomes with an IC50 of 91201.08. Bendazol inhibits the progression of form-deprivation myopia and suppresses HIF-1α upregulation.
|
|---|---|
| ln Vitro |
In vitro, Bendazol inhibits aminopyrine N-demethylase activity in hepatic microsomes. It enhances NO synthase activity. The compound is a vasodilator that acts on vascular smooth muscle. Its effects on NOS activation and enzyme inhibition have been characterized in various in vitro systems. Bendazol is used in cardiovascular and myopia research.
|
| ln Vivo |
In vivo, Bendazol is an orally effective hypotensive agent that dilates blood vessels and reduces peripheral resistance. It enhances NO synthase activity in renal glomeruli and collecting tubules. The compound inhibits the progression of form-deprivation myopia and suppresses HIF-1α upregulation. Its vasodilatory effects make it useful in the study of antihypertensive effects.
|
| Enzyme Assay |
In vitro enzyme assays for Bendazol involve measuring NOS activity. NOS activity is assessed by measuring nitric oxide production using the Griess assay or other methods. The compound is added at varying concentrations, and activation is quantified. Aminopyrine N-demethylase activity is assessed by measuring formaldehyde production. HIF-1α expression is measured by Western blot. Assays are performed in appropriate buffer systems with positive controls.
|
| Cell Assay |
In vitro cell-based assays for Bendazol are conducted in vascular smooth muscle cells and other relevant cell types. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. NO production is measured by Griess assay. Vasodilation is assessed by measuring vascular smooth muscle relaxation. Cell viability is assessed by standard assays. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Bendazol in vivo studies are conducted in animal models of hypertension and myopia. Animals are treated with Bendazol via oral administration. Blood pressure is monitored for antihypertensive effects. For myopia studies, form-deprivation myopia models are used and HIF-1α expression is assessed. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis at study endpoints.
|
| ADME/Pharmacokinetics |
Bendazol (MW 208.26 g/mol, C14H12N2) is a hypotensive drug. It is also known as Dibazol, Dibazole, Bendazole, and Tromasedan. The compound is soluble in DMSO and other organic solvents. It is stable under recommended storage conditions. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies. Bendazol is used in cardiovascular and myopia research.
|
| Toxicity/Toxicokinetics |
Bendazol is generally well-tolerated at therapeutic doses. The compound is a hypotensive drug with established safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Bendaazole belongs to the benzimidazole class of compounds. It has been reported that star anise contains benzimidazole, and relevant data is available for reference.
Bendazol (Dibazol, 2-Benzylbenzimidazole) is a hypotensive drug that enhances NO synthase activity in renal glomeruli and collecting tubules. It acts as a vasodilator, reducing peripheral resistance. The compound inhibits form-deprivation myopia progression and HIF-1α upregulation. Its molecular formula is C14H12N2 with a molecular weight of 208.26 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C14H12N2
|
|---|---|
| Molecular Weight |
208.25848
|
| Exact Mass |
208.1
|
| CAS # |
621-72-7
|
| Related CAS # |
621-72-7;1212-48-2 (HCl);
|
| PubChem CID |
12132
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
453.5±24.0 °C at 760 mmHg
|
| Melting Point |
187ºC
|
| Flash Point |
252.1±9.3 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.680
|
| LogP |
3.93
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
223
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
YTLQFZVCLXFFRK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H12N2/c1-2-6-11(7-3-1)10-14-15-12-8-4-5-9-13(12)16-14/h1-9H,10H2,(H,15,16)
|
| Chemical Name |
2-benzyl-1H-benzimidazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~480.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8017 mL | 24.0085 mL | 48.0169 mL | |
| 5 mM | 0.9603 mL | 4.8017 mL | 9.6034 mL | |
| 10 mM | 0.4802 mL | 2.4008 mL | 4.8017 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
